Literature DB >> 4192136

Treatment of Wilson's disease with L-dopa after failure with penicillamine.

A Barbeau, H Friesen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4192136     DOI: 10.1016/s0140-6736(70)91259-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 3.  Dopamine and disease.

Authors:  A Barbeau
Journal:  Can Med Assoc J       Date:  1970-10-17       Impact factor: 8.262

4.  L-dopa and amantadine hydrochloride in extra-pyramidal disorders.

Authors:  J D Parkes; R P Knill-Jones; P J Clements
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

5.  Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease.

Authors:  Henryk Barthel; Wieland Hermann; Regine Kluge; Swen Hesse; David R Collingridge; Armin Wagner; Osama Sabri
Journal:  AJNR Am J Neuroradiol       Date:  2003-02       Impact factor: 3.825

6.  Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1972-06-10       Impact factor: 8.262

7.  Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.

Authors:  B Jeon; J M Kim; J M Jeong; K M Kim; Y S Chang; D S Lee; M C Lee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.